Drug intelligence / Profile preview

autologous mesenchymal stromal cells (Fundación Instituto de Ciencias de la Salud de Castilla y León)

Development stage
Unknown
Lead developer
Fundación Instituto de Ciencias de la Salud de Castilla y León
Modality
Stem Cell Therapies → Cell Therapies
Administration
Intraarticular
01

Overview

**Autologous mesenchymal stromal cells** are a patient-specific, culture-expanded bone marrow-derived mesenchymal stromal cell therapy being developed by Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León for intra-articular treatment of knee osteoarthritis. In the Phase III ARTROCELL study, the investigational product is administered as a single intra-articular knee injection and is evaluated against allogeneic bone marrow-derived mesenchymal stromal cells and hyaluronic acid. The therapeutic rationale is that MSCs can exert local paracrine immunomodulatory, anti-inflammatory, trophic, and tissue-homeostasis effects within the osteoarthritic joint; however, no single molecular target or clinically established cartilage-regeneration mechanism has been defined for this product.

Other names
autologous bone marrow-derived mesenchymal stromal cellsautologous MSCsautologous BM-MSCs

Beyond the preview

Go deeper on autologous mesenchymal stromal cells (Fundación Instituto de Ciencias de la Salud de Castilla y León).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous mesenchymal stromal cells (Fundación Instituto de Ciencias de la Salud de Castilla y León).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call